Stents show promise for rare gut artery tear
NCT ID NCT05171842
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the safety and effectiveness of using stents (small mesh tubes) to treat a tear in the main artery supplying the gut. 136 patients with this rare condition were treated and followed for 12 months. The goal was to see how many needed a second procedure and to check for complications like stent blockage or death.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
136 people
The number who actually took part.
- Started
-
Sep 2021
- Finished
-
Feb 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
SIDSMA patients receiving stent therapy
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Superior mesenteric artery dissection with obvious abdominal symptoms within 1 month of onset * CTA/DSA diagnosed as spontaneous superior mesenteric artery dissection; ③ CTA/DSA diagnosed as a solitary superior mesenteric artery dissection; ④ Sign the informed consent form and be willing to accept follow-up observation; Exclusion Criteria: 1. Those suffering from mental illness or subjectively unable to cooperate; 2. Patients with asymptomatic spontaneous solitary superior mesenteric artery dissection or only superior mesenteric artery intermural hematoma; 3. Patients with signs of peritonitis (tenderness, rebound pain, flat abdomen) and suggest severe intestinal ischemia; 4. Patients with strangulated intestinal obstruction; 5. Other patients who plan to undergo open surgery; 6. Women who are breastfeeding or pregnant, or women or men who have recent birth plans; 7. Life expectancy \<2 years; 8. Patients who are currently participating in other interventional drug or device research, or have been enrolled in this research; 9. Patients with renal failure or chronic kidney disease have MDRD GFR ≤ 30ml/min/1.73 m2 (or serum creatinine ≥2.5 mg/dL within 30 days before surgery, or receive dialysis treatment); 10. Diagnose active systemic infection or uncontrolled coagulation dysfunction within 14 days before operation; 11. History of previous superior mesenteric artery surgery; 12. Failure to take medications as required by the protocol, or allergy to antiplatelet drugs (aspirin or clopidogrel), low molecular weight heparin, vasodilators or contrast agents, so that the preoperative and postoperative medication requirements cannot be fully complied with 13. Combined with systemic diseases that cannot be controlled by the current medical level (such as severe heart function, lung function or liver function abnormalities, patients with advanced tumors, patients with cachexia, patients with severe coronary heart disease that cannot be relieved, abnormal blood coagulation caused by genetic diseases, etc.) 14. Cerebral hemorrhage, symptomatic stroke, myocardial infarction, gastrointestinal hemorrhage in the past 6 months or the patient is under 18 years of age or the patient refuses to participate in the study 15. Does not meet the expected intraoperative and postoperative treatment plan 16. The diameter of the true lumen in the anchoring area of the SMA distal stent is less than 3mm
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Dissection of the superior mesenteric artery are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
First Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, 310000, China